Niraparib in Tumors Metastatic to the CNS

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Massachusetts General Hospital
Study ID
NCT04992013
Phase
PHASE2
Status
Active Not Recruiting

Conditions

  • Central Nervous System Cancer
  • Metastatic Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This research is being done to see how effective the drug niraparib is against cancer that has metastasized to the central nervous system (CNS). * This research study involves the study drug niraparib.

Key Dates

Start date
Apr 5, 2022
Status verified
May 2026
Primary completion
Dec 1, 2026
Completion
Jun 1, 2027

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Niraparib
    Participants will receive niraparib 1x daily for each 28 day study treatment cycle up to 2 years or until disease worsens or unacceptable side effects occur.

Primary Outcome Measure

Intracranial Clinical benefit rate [ Time Frame: 8 Weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Massachusetts General Hospital Cancer CenterBostonMassachusetts02114-

Find similar trials in Boston, MA

By research site
Massachusetts General Hospital Cancer Center· Boston, MA

Related Studies